Literature DB >> 24145241

Stem cells and targeted approaches to melanoma cure.

George F Murphy1, Brian J Wilson2, Sasha D Girouard3, Natasha Y Frank4, Markus H Frank5.   

Abstract

Melanoma stem cells, also known as malignant melanoma-initiating cells, are identifiable through expression of specific biomarkers such as ABCB5 (ATP-binding cassette, sub-family B (MDR/TAP), member 5), NGFR (nerve growth factor receptor, CD271) and ALDH (aldehyde dehydrogenase), and drive melanoma initiation and progression based on prolonged self-renewal capacity, vasculogenic differentiation and immune evasion. As we will review here, specific roles of these aggressive subpopulations have been documented in tumorigenic growth, metastatic dissemination, therapeutic resistance, and malignant recurrence. Moreover, recent findings have provided pre-clinical proof-of-concept for the potential therapeutic utility of the melanoma stem cell concept. Therefore, melanoma stem cell-directed therapeutic approaches represent promising novel strategies to improve therapy of this arguably most virulent human cancer.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ABCB5; Cancer stem cell; Drug resistance; Immune evasion; Melanoma; Therapy; Vasculogenic mimicry

Mesh:

Year:  2013        PMID: 24145241      PMCID: PMC3992197          DOI: 10.1016/j.mam.2013.10.003

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  131 in total

1.  RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells.

Authors:  Verena Kupas; Carsten Weishaupt; Dorothee Siepmann; Maria-Laura Kaserer; Mareike Eickelmann; Dieter Metze; Thomas A Luger; Stefan Beissert; Karin Loser
Journal:  J Invest Dermatol       Date:  2011-01-27       Impact factor: 8.551

2.  Molecular classification of cutaneous malignant melanoma by gene expression profiling.

Authors:  M Bittner; P Meltzer; Y Chen; Y Jiang; E Seftor; M Hendrix; M Radmacher; R Simon; Z Yakhini; A Ben-Dor; N Sampas; E Dougherty; E Wang; F Marincola; C Gooden; J Lueders; A Glatfelter; P Pollock; J Carpten; E Gillanders; D Leja; K Dietrich; C Beaudry; M Berens; D Alberts; V Sondak
Journal:  Nature       Date:  2000-08-03       Impact factor: 49.962

3.  VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth.

Authors:  Natasha Y Frank; Tobias Schatton; Soo Kim; Qian Zhan; Brian J Wilson; Jie Ma; Karim R Saab; Veronika Osherov; Hans R Widlund; Martin Gasser; Ana-Maria Waaga-Gasser; Thomas S Kupper; George F Murphy; Markus H Frank
Journal:  Cancer Res       Date:  2011-01-06       Impact factor: 12.701

Review 4.  Melanocyte biology and skin pigmentation.

Authors:  Jennifer Y Lin; David E Fisher
Journal:  Nature       Date:  2007-02-22       Impact factor: 49.962

5.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Authors:  Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé
Journal:  Lancet Oncol       Date:  2009-12-08       Impact factor: 41.316

6.  ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome.

Authors:  Aaron M Elliott; Muhammad A Al-Hajj
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

7.  Identification of cells initiating human melanomas.

Authors:  Tobias Schatton; George F Murphy; Natasha Y Frank; Kazuhiro Yamaura; Ana Maria Waaga-Gasser; Martin Gasser; Qian Zhan; Stefan Jordan; Lyn M Duncan; Carsten Weishaupt; Robert C Fuhlbrigge; Thomas S Kupper; Mohamed H Sayegh; Markus H Frank
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962

8.  Phase I/II trial of tremelimumab in patients with metastatic melanoma.

Authors:  Luis H Camacho; Scott Antonia; Jeffrey Sosman; John M Kirkwood; Thomas F Gajewski; Bruce Redman; Dmitri Pavlov; Cecile Bulanhagui; Viviana A Bozon; Jesus Gomez-Navarro; Antoni Ribas
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544

9.  The regenerative capacity of the zebrafish caudal fin is not affected by repeated amputations.

Authors:  Ana Sofia Azevedo; Bartholomäus Grotek; António Jacinto; Gilbert Weidinger; Leonor Saúde
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240

10.  A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.

Authors:  E Stockert; E Jäger; Y T Chen; M J Scanlan; I Gout; J Karbach; M Arand; A Knuth; L J Old
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

View more
  24 in total

1.  The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane.

Authors:  Matthew L Fisher; Gautam Adhikary; Dan Grun; David M Kaetzel; Richard L Eckert
Journal:  Mol Carcinog       Date:  2015-12-23       Impact factor: 4.784

Review 2.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

3.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

Review 4.  Cancer Stem Cells (CSCs) in melanoma: There's smoke, but is there fire?

Authors:  Constance E Brinckerhoff
Journal:  J Cell Physiol       Date:  2017-03-06       Impact factor: 6.384

5.  Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.

Authors:  Fang Zheng; Jianzhong Dang; Hongyu Zhang; Fangzhou Xu; Diandian Ba; Bingyu Zhang; Fanjun Cheng; Alfred E Chang; Max S Wicha; Qiao Li
Journal:  J Immunother       Date:  2018-10       Impact factor: 4.456

6.  Stem cells' guided gene therapy of cancer: New frontier in personalized and targeted therapy.

Authors:  Maria Mavroudi; Paul Zarogoulidis; Konstantinos Porpodis; Ioannis Kioumis; Sofia Lampaki; Lonny Yarmus; Raf Malecki; Konstantinos Zarogoulidis; Marek Malecki
Journal:  J Cancer Res Ther (Manch)       Date:  2014

7.  Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells.

Authors:  Mary Jc Hendrix; Irawati Kandela; Andrew P Mazar; Elisabeth A Seftor; Richard Eb Seftor; Naira V Margaryan; Luigi Strizzi; George F Murphy; Georgina V Long; Richard A Scolyer
Journal:  Lab Invest       Date:  2016-10-24       Impact factor: 5.662

8.  ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit.

Authors:  Brian J Wilson; Karim R Saab; Jie Ma; Tobias Schatton; Pablo Pütz; Qian Zhan; George F Murphy; Martin Gasser; Ana Maria Waaga-Gasser; Natasha Y Frank; Markus H Frank
Journal:  Cancer Res       Date:  2014-06-16       Impact factor: 12.701

9.  Potential function of CTLA-4 in the tumourigenic capacity of melanoma stem cells.

Authors:  Bingyu Zhang; Jianzhong Dang; Diandian Ba; Cencen Wang; Juan Han; Fang Zheng
Journal:  Oncol Lett       Date:  2018-08-23       Impact factor: 2.967

Review 10.  Aldehyde dehydrogenase-positive melanoma stem cells in tumorigenesis, drug resistance and anti-neoplastic immunotherapy.

Authors:  Simin Zhang; Zhen Yang; Fazhi Qi
Journal:  Mol Biol Rep       Date:  2019-12-14       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.